Advanced search
Publication Cover
COPD: Journal of Chronic Obstructive Pulmonary Disease Volume 13, 2016 - Issue 2
Submit an article Journal homepage
1,620
Views
13
CrossRef citations to date
0
Altmetric
Original Research

A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI

Suyong Yun KirbyGSK, Research Triangle Park, North Carolina, USACorrespondence[email protected]
,
Chang-Qing ZhuGSK, Uxbridge, Middlesex, United Kingdom
,
Edward M. KerwinClinical Research Institute of Southern Oregon, Medford, Oregon, USA
,
Richard H. StanfordGSK, Research Triangle Park, North Carolina, USA
&
George GeorgesGSK, Research Triangle Park, North Carolina, USA
Pages 167-175 | Published online: 30 Oct 2015

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Chitra Lal & Charlie Strange. (2019) Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opinion on Pharmacotherapy 20:9, pages 1075-1085.
Read now
Antonio Molino, Giovanna Calabrese & Mauro Maniscalco. (2018) Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol. Patient Preference and Adherence 12, pages 993-1001.
Read now
Timothy E Albertson, Samuel W Bullick, Michael Schivo & Mark E Sutter. (2016) Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy. Drug Design, Development and Therapy 10, pages 4047-4060.
Read now

Articles from other publishers (10)

Yuqing Ye, Ying Ma & Jesse Zhu. (2022) The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders?. International Journal of Pharmaceutics 614, pages 121457.
Crossref
Mohamed E. A. Abdelrahim, Haitham Saeed, Hadeer S. Harb & Yasmin M. MadneyMohamed E. A. Abdelrahim, Haitham Saeed, Hadeer S. Harb & Yasmin M. Madney. 2021. Essentials of Aerosol Therapy in Critically ill Patients. Essentials of Aerosol Therapy in Critically ill Patients 89 114 .
Mohamed E. A. Abdelrahim, Haitham Saeed, Hadeer S. Harb & Yasmin M. MadneyMohamed E. A. Abdelrahim, Haitham Saeed, Hadeer S. Harb & Yasmin M. Madney. 2021. Essentials of Aerosol Therapy in Critically ill Patients. Essentials of Aerosol Therapy in Critically ill Patients 65 88 .
Haitham Saeed, Heba F. Salem, Hoda Rabea & Mohamed E. A. Abdelrahim. (2018) Effect of Human Error, Inhalation Flow, and Inhalation Volume on Dose Delivery from Ellipta® Dry-Powder Inhaler. Journal of Pharmaceutical Innovation 14:3, pages 239-244.
Crossref
Chaeho Moon, Hugh D. C. Smyth, Alan B. Watts & Robert O. WilliamsIIIIII. (2019) Delivery Technologies for Orally Inhaled Products: an Update. AAPS PharmSciTech 20:3.
Crossref
Hong-Goo Lee, Dong-Wook Kim & Chung-Woong Park. (2017) Dry powder inhaler for pulmonary drug delivery: human respiratory system, approved products and therapeutic equivalence guideline. Journal of Pharmaceutical Investigation 48:6, pages 603-616.
Crossref
Muhammad Suleman Khan & Michael S. Roberts. (2018) Challenges and innovations of drug delivery in older age. Advanced Drug Delivery Reviews 135, pages 3-38.
Crossref
Henrik Svedsater, Helen A. Doll, Jake Macey, Gail Miles, Lisa Bradshaw & Magdalena Vanya. (2018) Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences. Advances in Therapy 35:9, pages 1378-1399.
Crossref
Thomas L Jones, Daniel M Neville & Anoop J Chauhan. (2018) The Ellipta ® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability . Therapeutic Delivery 9:3, pages 169-176.
Crossref
Nicole Rockich-Winston, Chris Gillette, Brian Train, Amber S Tippens, Susan Flesher & Meagan Shepherd. (2016) A model to integrate patient preferences into delivery systems: the importance of end-user input into pulmonary delivery. Therapeutic Delivery 7:9, pages 591-593.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.